Skip to content
Log in Join free
Life Sciences 360 cover art

Harsh Thakkar

Life Sciences 360

A Life Sciences and Science podcast

#148 in Life Sciences · 🇮🇳
Good podcast? Give it some love!

About the show

Life Sciences 360 is an interview show that educates anyone on challenges, trends, and insights in the life-sciences industry. Hosted by Harsh Thakkar, a life-sciences industry veteran and CEO and co-founder of Qualtivate, the show features subject-matter experts, business leaders, and key life-science partners contributing to bringing new therapies to patients worldwide. Harsh is passionate about advancements in life sciences and tech and is always eager to learn from his guests— making the show both informative and useful.

Newest episodes

Why Every Medical Affairs Team Needs Their Own AI Agent in 2025

48 min

Medical misinformation, life sciences burnout, and AI-powered content creation collide in this episode with Dr. Ome Ogbru, founder & CEO of AINGENS and creator of MACg (Medical Affairs Content Generator).  Learn how AI in biotech is tackling the complexities of medical affairs—from literature review and content automation to compliance and regulatory writing. ⚡️ WHAT YOU’LL LEARN: - Why medical affairs and regulatory teams can’t rely on ChatGPT alone. - How MACg integrates real‑time PubMed search, citation generation, and secured collaboration to streamline scientific writing  - Why MACg users report up to 50 % faster writing and 50–70 % faster medical-legal review. - Why AI platforms like MACg must be purpose-built for life sciences (GDPR & SOC 2 compliant). - What is “human-in-the-loop” AI workflow—and how it balances automation and review to maintain accuracy and trust. - Real-world use cases: scientific summaries, medical info letters and more. 🎙️ Guest: Ome Ogbru | Founder and President of AINGENS 🔗 Connect with Ome: LinkedIn For transcripts, check out the podcast website - www.lifesciencespod.com

VC Money Tight? Here’s How Startups Still Land Top Talent (2025)

46 min

What happens when 3,500 staffers lose their jobs due to FDA layoffs, venture capital (VC) term sheets shrink, and AI drug-discovery startups raise $600 million rounds?  Executive recruiter William Holodnak (ex-Fidelity, global biotech headhunter) breaks down 2025’s wild hiring market—and how founders can still build A-teams. In this episode you’ll learn: - Why the April-1 FDA layoffs could delay approvals—and open new career doors for ex-regulators.  - The three traits VCs demand in first-time biotech CEOs during a funding slump.  - How AI-driven platforms like Isomorphic Labs raised mega-rounds in a down market.  - Immunology’s surge and why oncology startups are pivoting.  - Board-level recruiting tactics that de-risk your Series B. 🎙️ Guest: William Holodnak | Founder and President of Occam Global 🔗 Connect with Bill: LinkedIn 📌 Chapters: 00:00 Intro 05:45 Cambridge—“the Florence of Biotech” origin story 08:20 FDA layoffs: threat or opportunity? 13:30 Biotech venture capital mood swings & funding checkpoints 18:00 What VCs really screen for in scientific founders 25:05 The “horses for courses” CEO model explained 33:00 Hot therapeutic areas: AI drug discovery, immunology, repurposing 38:30 Why boards need operators, not just investors 47:00 Career improvisation: William’s closing advice For transcripts, check out the podcast website - www.lifesciencespod.com

Why Most Healthcare Brands Fail (And How to Fix It)

50 min

Why Most Healthcare Brands Fail (And How to Fix It) In this episode, Holley Miller, Founder and President of Grey Matter Marketing, reveals why most medtech and life sciences companies fail to connect with their audience—and how to fix that with brand clarity and strategic storytelling. You’ll learn how marketing in regulated industries is evolving, why flashy tactics often fall flat, and how brand equity is built through consistency, credibility, and emotional connection. Holley also shares lessons from working with emerging startups and large enterprises, offering a strategy for aligning commercial goals with patient and provider trust. 🎙️ Guest: Holley Miller | Founder and President of Grey Matter Marketing 🔗 Connect with Holley: LinkedIn 📌 Chapters: 00:00 The Journey of Grey Matter: 19 Years in Life Science Marketing 02:45 Evolution of Marketing in Life Sciences 05:59 Category Design: Creating and Owning a Market 08:54 Understanding Problems: The Key to Category Creation 12:02 Building the Right Team for Success 14:57 Painkillers vs. Vitamins: Motivating Change in Healthcare 27:30 Life Sciences Market Domination Framework 34:27 The Four Pillars of Market Success 42:31 Market Domination Scorecard: Assessing Your Strategy 45:09 What Matters: The Impact of Your Work 48:39 Finding Your Superpower Subscribe for more insights on the latest in Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com

Similar podcasts

All episodes

Why Every Medical Affairs Team Needs Their Own AI Agent in 2025

48 min

Medical misinformation, life sciences burnout, and AI-powered content creation collide in this episode with Dr. Ome Ogbru, founder & CEO of AINGENS and creator of MACg (Medical Affairs Content Generator).  Learn how AI in biotech is tackling the complexities of medical affairs—from literature review and content automation to compliance and regulatory writing. ⚡️ WHAT YOU’LL LEARN: - Why medical affairs and regulatory teams can’t rely on ChatGPT alone. - How MACg integrates real‑time PubMed search, citation generation, and secured collaboration to streamline scientific writing  - Why MACg users report up to 50 % faster writing and 50–70 % faster medical-legal review. - Why AI platforms like MACg must be purpose-built for life sciences (GDPR & SOC 2 compliant). - What is “human-in-the-loop” AI workflow—and how it balances automation and review to maintain accuracy and trust. - Real-world use cases: scientific summaries, medical info letters and more. 🎙️ Guest: Ome Ogbru | Founder and President of AINGENS 🔗 Connect with Ome: LinkedIn For transcripts, check out the podcast website - www.lifesciencespod.com

VC Money Tight? Here’s How Startups Still Land Top Talent (2025)

46 min

What happens when 3,500 staffers lose their jobs due to FDA layoffs, venture capital (VC) term sheets shrink, and AI drug-discovery startups raise $600 million rounds?  Executive recruiter William Holodnak (ex-Fidelity, global biotech headhunter) breaks down 2025’s wild hiring market—and how founders can still build A-teams. In this episode you’ll learn: - Why the April-1 FDA layoffs could delay approvals—and open new career doors for ex-regulators.  - The three traits VCs demand in first-time biotech CEOs during a funding slump.  - How AI-driven platforms like Isomorphic Labs raised mega-rounds in a down market.  - Immunology’s surge and why oncology startups are pivoting.  - Board-level recruiting tactics that de-risk your Series B. 🎙️ Guest: William Holodnak | Founder and President of Occam Global 🔗 Connect with Bill: LinkedIn 📌 Chapters: 00:00 Intro 05:45 Cambridge—“the Florence of Biotech” origin story 08:20 FDA layoffs: threat or opportunity? 13:30 Biotech venture capital mood swings & funding checkpoints 18:00 What VCs really screen for in scientific founders 25:05 The “horses for courses” CEO model explained 33:00 Hot therapeutic areas: AI drug discovery, immunology, repurposing 38:30 Why boards need operators, not just investors 47:00 Career improvisation: William’s closing advice For transcripts, check out the podcast website - www.lifesciencespod.com

Why Most Healthcare Brands Fail (And How to Fix It)

50 min

Why Most Healthcare Brands Fail (And How to Fix It) In this episode, Holley Miller, Founder and President of Grey Matter Marketing, reveals why most medtech and life sciences companies fail to connect with their audience—and how to fix that with brand clarity and strategic storytelling. You’ll learn how marketing in regulated industries is evolving, why flashy tactics often fall flat, and how brand equity is built through consistency, credibility, and emotional connection. Holley also shares lessons from working with emerging startups and large enterprises, offering a strategy for aligning commercial goals with patient and provider trust. 🎙️ Guest: Holley Miller | Founder and President of Grey Matter Marketing 🔗 Connect with Holley: LinkedIn 📌 Chapters: 00:00 The Journey of Grey Matter: 19 Years in Life Science Marketing 02:45 Evolution of Marketing in Life Sciences 05:59 Category Design: Creating and Owning a Market 08:54 Understanding Problems: The Key to Category Creation 12:02 Building the Right Team for Success 14:57 Painkillers vs. Vitamins: Motivating Change in Healthcare 27:30 Life Sciences Market Domination Framework 34:27 The Four Pillars of Market Success 42:31 Market Domination Scorecard: Assessing Your Strategy 45:09 What Matters: The Impact of Your Work 48:39 Finding Your Superpower Subscribe for more insights on the latest in Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com

4.5 Billion Molecules, One Mission: Cure the ‘Undruggable’ Diseases

30 min

Solving the “Undruggable” Disease Problem with Goldilocks Molecules In this episode, Christian Schafmeister, Founder and President of Third Law Molecular, reveals a new class of therapeutics designed to target what most consider “undruggable” diseases—conditions like Alzheimer’s, certain cancers, and rare genetic disorders. Christian explains the science behind spiroligomers—modular, mid-sized molecules that act like molecular LEGOs, offering the perfect balance between small molecules and biologics. Learn how his team created a library of 4.5 billion molecules and what makes these structures uniquely suited to bind difficult protein targets, including disordered proteins and intracellular surfaces. We also talk about the Goldilocks Zone of drug design, how Third Law’s chemistry was born out of academic and defense-backed research, and why the future of drug discovery may lie in designing therapeutics that are just right. 🎙️ Guest: Christian Schafmeister | Founder and President at ThirdLaw Molecular 🔗 Connect with Christian: LinkedIn 🔗 ThirdLaw Molecular Website 🔗 Spiroligomers Presentation 📌 Chapters: 00:00 Introduction to Undruggable Diseases 01:30 Discovering Spiroligomers: A New Class of Molecules 08:04 Challenges in Targeted Drug Discovery 09:31 Building a Library of Molecules 14:47 The Birth of Third Law Molecular 17:19 The Goldilocks Molecule Concept 19:56 Applications in Cancer and Other Diseases 21:24 Collaborations with Big Pharma 23:39 Handling Clinical Trials 27:20 Future Directions and Industry Insights Subscribe for more insights on the latest in Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com

What Separates Life Science Startup Winners from Losers?

38 min

Why Startups Fail (Hint: It’s Not the Innovation) In this episode, Carlo Odicino, CEO and Founder at One TEAM Partners, shares the real reasons why most early-stage life sciences companies struggle to survive—and it has nothing to do with bad science. Learn the hidden pitfalls of scaling too fast, confusing innovation with execution, and chasing too many priorities at once. Carlo offers practical strategies for building focus, setting boundaries, and creating a people-first culture that actually scales. You’ll also learn why execution beats experimentation when commercial success is the goal—and how to stay aligned with investors without over-promising. This conversation is packed with actionable advice for startup leaders, biotech founders, and anyone facing the complexities of early-stage growth. 🎙️ Guest: Carlo Odicino | CEO and Founder at One TEAM Partners 🔗 Connect with Carlo: LinkedIn 🔗 One Team Partners Website 📌 Chapters: 00:00 The Innovation-Execution Tension 07:30 Managing Investor Expectations 17:48 Establishing Core Values in Organizations 24:56 Work-Life Integration vs. Balance 35:11 The Role of Human Connection in Innovation Subscribe for more insights on the latest in Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com

Pandora's Box of Secrets EXPOSED in Drug Pricing Transparency!

30 min

The Hidden Math Behind Drug Pricing: Why Patients Pay More Than They Should In this episode, Michael Grosberg, VP of Product Management at Model N, breaks down the complex drug pricing ecosystem—revealing how rebates, PBMs, and outdated pricing models shape what patients actually pay. You’ll learn how Pharmacy Benefit Managers (PBMs) really operate, why list prices are misleading, and how pricing negotiations impact patient access. Michael also unpacks the mechanics behind patient assistance programs, the role of compounding and independent pharmacies, and how emerging technology can bring transparency and efficiency to a broken system. Whether you’re in life sciences, healthcare tech, or just want to understand why your prescription costs what it does—this is a must-listen conversation. 🎙️ Guest: Michael Grosberg | VP of Product Management at Model N 🔗 Connect with Michael Grosberg: LinkedIn 🔗 Model N LinkedIn 🔗 Model N 🔗 Drug Channels Institute  📌 Chapters: 00:00 Introduction to Pharmaceutical Pricing Dynamics 03:00 The Role of PBMs in Drug Affordability 06:13 Challenges with GLP-1 Medications and Independent Pharmacies 09:01 Understanding Drug Pricing and Stakeholder Dynamics 11:55 The Impact of List Prices on Patient Costs 15:05 Innovative Approaches to Healthcare Pricing 18:01 Patient Assistance Programs and Their Implications 20:44 The Role of Technology in Pharmaceutical Pricing 23:54 The Need for Transparency in Drug Pricing 26:59 Resources for Further Learning on Drug Pricing Subscribe for more insights on the latest in Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com

A CCO’s Brutally Honest Advice if You Want to Succeed in Pharma Commercialization

31 min

Early Commercialization Strategies That Actually Work (Especially for Startups!) In this episode, John Harlow, Chief Commercial Officer at Melinta Therapeutics, shares real-world strategies for how lean pharma startups can win the commercialization game—without Big Pharma budgets. Discover how small companies can pivot fast, creatively optimize distribution, and make strategic decisions without endless red tape. John breaks down the critical mindset shift from R&D to commercial readiness, how to build high-performing teams in resource-constrained environments, and why smaller organizations often out-execute the giants. We also discuss how to prioritize spend, what leaders should know before leaving Big Pharma, and the overlooked advantages of smaller teams. 🎙️ Guest: John Harlow | CCO of Melinta Therapeutics 🔗 Connect with John Harlow: LinkedIn 📌 Chapters: 00:00 The Challenges of Small Pharma 02:31 Understanding Melinta Therapeutics 04:44 Resource Constraints in Small Companies 08:30 The Speed of Decision-Making in Startups 10:15 Building a Cross-Functional Team 11:34 The Benefits of Small Team Dynamics 16:51 Case Study: Distribution Strategy Pivot 19:52 Creative Problem Solving in Resource Constraints 23:40 Staying Updated in the Pharma Space 27:34 Trends in Biotech and Pharma Startups 29:49 Building vs. Buying in Pharma Subscribe for more insights on Biotech and Pharma Startups! For transcripts, check out the podcast website - www.lifesciencespod.com

Digital Health Expert: THIS is the No.1 Roadblock to Healthcare AI Adoption

35 min

Healthcare AI adoption is transforming the way we address risk, confidentiality, and patient care. In this episode, RJ Kedziora, co-founder of Estenda Solutions talks about the practical steps to safely integrate AI in clinical workflows. Learn how to manage data privacy, mitigate algorithmic bias, and keep a human in the loop to prevent misdiagnoses. Discover real-world strategies for using AI ethically, from ambient listening to second-opinion checks, and why it’s irresponsible not to harness AI’s potential. The discussion also highlights how AI can enhance the roles of healthcare professionals, ultimately improving patient outcomes. 🎙️ Guest: Richard Kedziora | co-founder/COO of Estenda Solutions 🔗 Connect with Richard Kedziora: LinkedIn  📌 Chapters: 00:00 Introduction to AI in Healthcare 03:01 Understanding Risks in AI Implementation 06:02 Confidentiality and Data Protection 09:03 Ethics and Explainability in AI 11:52 Bias in AI and Its Implications 15:09 Mitigating Risks in AI Usage 17:51 The Role of Humans in AI Decision Making 21:04 AI Enhancing Healthcare Professionals' Roles 24:10 Future of AI in Healthcare 26:57 Final Thoughts and Resources Subscribe for more insights on AI in Healthcare! For transcripts, check out the podcast website - www.lifesciencespod.com

Tired of Supply Chain Errors? Here’s the Fix: Drug Serialization for DSCSA Compliance

39 min

Drug serialization is at the heart of modern pharmaceutical supply chain security. In this episode  Michael Rowe, Senior Director of DSCSA and Serialization Services at TwoLabs, talks about the critical role of drug serialization and DSCSA compliance in safeguarding the pharmaceutical supply chain. Michael explains how unique serial numbers, standardized data, and digital traceability are revolutionizing how drugs are tracked from manufacturer to pharmacy. Discover real-world challenges and innovative solutions that ensure product integrity, reduce counterfeiting, and enhance operational efficiency in the pharma industry. Whether you're involved in manufacturing, distribution, or regulatory affairs, learn how embracing drug serialization and DSCSA compliance can transform your operations. 🎙️ Guest: Michael Rowe | Senior Director of DSCSA and Serialization Services at TwoLabs 🔗 Connect with Michael Rowe: LinkedIn 📲 Learn more about TwoLabs  More information on FDA and DSCSA 📌 Chapters: 00:00 Introduction to DSCSA and Its Importance 03:07 Understanding the Drug Supply Chain Security Act 05:54 The Role of Serialization in Drug Traceability 09:04 Impact of DSCSA on Different Stakeholders 11:54 Challenges in Compliance and Operational Changes 15:01 The Role of Technology in DSCSA Compliance 20:21 Blockchain Challenges and Opportunities 22:47 AI in Exception Handling 27:38 Client Approaches: From Strategy to Implementation 32:12 Real-World Compliance Success Stories 35:53 Consequences of Non-Compliance 38:29 Resources for DSCSA Compliance Subscribe for more insights on Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com

Why Equitable Healthcare is the KEY to Better Health

22 min

Equitable healthcare is the key to bridging health gaps and creating better patient outcomes. In this episode, Amy West, Principal, Advisory Services at HitLab, share her insights on how technology, digital health, and data can reshape access to care—especially for underserved communities. Learn how addressing social determinants, using remote patient monitoring, and integrating wearables can empower patients and reduce disparities. From real-world examples to actionable insights, Amy shares a vision for a more inclusive and effective healthcare system. Whether you’re a clinician, policymaker, or simply curious about the future of medicine, discover how innovative tools and a patient-centric approach can pave the way for true health equity. 🎙️ Guest: Amy West | Principal, Advisory Services & Chair for the Women’s Health Tech Initiative at HITLAB 🔗 Connect with Amy West: LinkedIn  📲 Learn more about HITLAB 📌 Chapters: 00:00-Exploring Healthcare Accessibility 06:49-Understanding Social Determinants of Health 12:00-The Role of Technology in Healthcare 17:51-Barriers in Women's Health 20:06-Future Trends in Digital Health Subscribe for more insights on healthcare! For transcripts, check out the podcast website - www.lifesciencespod.com

Can AI Help Doctors Find Cancer Faster?

36 min

Have you ever wondered if AI could help doctors find cancer faster and more accurately? In this episode, we explore OmniScreen, an AI-powered biomarker tool that is revolutionizing cancer diagnostics. Joe Oakley, a pathologist and expert in digital pathology, explains how OmniScreen was trained on 3 million digital slides to detect cancer biomarkers with higher precision and speed. He shares how AI is reducing testing time, preserving tissue samples, and improving early cancer detection. We also tackle the big question: Will AI replace pathologists? Joe breaks down the role of AI in pathology and why it should be seen as a tool to assist rather than replace doctors. Plus, learn how AI is helping hospitals, pharmaceutical companies, and researchers in drug development and clinical trials. 🔹 Key Topics Covered: ✔️ How OmniScreen is transforming cancer diagnostics ✔️ AI vs. traditional cancer detection methods ✔️ The role of AI in hospitals, pharma, and research ✔️ Will AI replace pathologists? The expert’s take ✔️ The future of AI-driven cancer research 🎙️ Guest: Joe Oakley, Lead Consultant/ Founder at Oakley Pathology Consultants, LLC 🔗 Connect with Joe Oakley: LinkedIn  📌 Chapters: 00:00 Introduction 00:49 The problem: Can AI find cancer faster? 01:19 How OmniScreen speeds up cancer detection 01:58 The AI behind OmniScreen: Trained on 3 million slides 02:28 How cancer diagnosis worked before AI 04:31 The evolution of pathology and diagnostic tools 06:10 Why AI can detect cancer better than traditional tests 07:24 How OmniScreen works step by step 08:34 The real impact: Saving time, tissue, and costs 10:04 Who are the early adopters of OmniScreen? 11:59 The role of hospitals, pharma, and researchers 14:12 The cost of AI-driven cancer detection 15:52 The big debate: Will AI replace pathologists? 17:10 Why AI is a tool, not a replacement 19:35 Future impact on drug development and clinical trials 22:09 AI’s role in personalized medicine 24:42 The future of AI in can...

Why Science Marketing Will Make Your Company EXPLODE in 2025?

44 min

Have you ever wondered why marketing in the life sciences industry is so different from traditional marketing? In this episode, we dive deep into the power of science marketing, the impact of brand storytelling, and how companies can successfully position their products in a competitive market. From publishing content to collaboration with industry, we'll show you how to harness the power of science marketing for success. Why do some breakthrough innovations never reach their full potential, while others become industry leaders? Our guest, Elizabeth Chabe, is the CEO of High Touch Group and a leading expert in scientific marketing. She shares invaluable insights on how companies can build credibility, shorten sales cycles, and effectively communicate complex innovations to investors, researchers, and the public. We also explore: ✅ Why scientific breakthroughs fail without proper marketing  ✅ The biggest mistakes life sciences companies make  ✅ How to pitch complex ideas to experts & decision-makers  ✅ The secret behind pharma ads & storytelling in healthcare  ✅ How conferences & live demonstrations can transform your brand  This episode is packed with expert strategies, real-world examples, and game-changing marketing insights for biotech, medtech, and pharma professionals. ⏱️ Chapters: 00:00 Introduction 02:24 Why Science Marketing is Crucial 05:38 How to Tailor Your Message for Experts 14:29 The ROI of Marketing – Why It’s a Game Changer 22:24 The Secret Behind Pharma Ads & Storytelling 27:31 A Genius Conference Marketing Strategy 32:25 The Future of Science Marketing & Live Engagement 35:04 Why Elizabeth Runs a Global Business 38:50 A Sneak Peek Into Her Book – The Giants Ladder 42:31 Final Thoughts & Takeaways 🔗 Links Mentioned: 📌 Connect with Elizabeth Chabe on LinkedIn: https://www.linkedin.com/in/eviselli/ 📌 Learn more about the work she does at High Touch Group 📌 Grab a copy of Elizabeth's book, The Giants Ladder For transcripts, check out th...

Why Most New Drugs Don't Launch: The Hidden Challenges in Pharma

37 min

Have you ever wondered why so many new drugs fail even after years of research and billions in investment? In this episode, we dive deep into the challenges of drug commercialization, the role of AI in pharma, and the biggest mistakes companies make before going to market. Our guest, Dan Cummings, is a leading expert in go-to-market strategy, having worked with top health tech, medtech, and biotech startups. He shares insider insights on why even successful clinical trials don’t guarantee a product’s success and how companies can improve their chances. We also explore: - The shocking statistics behind drug approvals  - Why less than a third of new drugs in 2025 will meet expectations - The #1 mistake pharma companies make before launch  - How AI is transforming drug development & commercialization  - What makes some drugs cost millions of dollars, while others are much cheaper  This episode is packed with industry insights, expert opinions, and bold predictions about the future of pharmaceuticals. Chapters: 00:00 Introduction03:54 The Challenges of Drug Commercialization05:35 Market Access & Value-Based Pricing12:00 Predictions for 2025 Drug Approvals13:23 The Role of AI in Pharma16:59 Why Most Drug Launches Miss Expectations18:25 Lessons from Biotech Success Stories23:46 The Future of Pharma & Go-to-Market Strategies29:31 How Companies Can Improve Their Launch Success35:56 Final Thoughts & Takeaways 🔗 Links Mentioned: 📌 Connect with Dan Cummings on LinkedIn 📌 Learn more about Envision Pharma Group If you enjoyed this, you'll like these other past episodes: How to Combine Storytelling and Science for Impact Understanding Drug Pricing and the Impact of the Inflation Reduction Act For transcripts, check out the podcast website - www.lifesciencespod.com

Why 55% of Clinical Trials Fail – The Truth About Drug Development

43 min

Have you ever wondered why so many clinical trials fail before reaching the market? In this episode, we dive deep into the hidden challenges of clinical trials with Rob Freishtat, President and Co-Founder of Uncommon Cures and a professor at George Washington University School of Medicine and Health Sciences. Rob shares insider knowledge on why over 55% of clinical trials fail, the high costs of drug development, and how misaligned priorities between researchers, regulators, and sponsors can derail promising treatments. He also reveals how streamlining clinical trials, improving patient recruitment, and leveraging AI and real-world data can help bring life-saving drugs to market faster. If you're curious about the future of medicine, drug approvals, or how rare disease treatments are developed, this is an episode you don’t want to miss! Chapters: 00:00 Introduction – Why Clinical Trials Matter 02:59 The Real Reason Many Clinical Trials Fail 08:18 Where the Industry Wastes the Most Money 15:28 How Misalignment in Drug Development Happens 27:00 The Future of AI in Clinical Trials 34:19 How to Fix Broken Clinical Trials 41:03 Final Thoughts & Key Takeaways 🔗 Links Mentioned: 🌐 Visit Uncommon Cures 📌 Follow Rob Freishtat on LinkedIn More from Life Sciences 360: 🎥 Youtube:/ @lifesciences360 For transcripts, check out the podcast website - www.lifesciencespod.com

How to Get Quick Access to GLP-1 Medications without Health Insurance ft. Dr. Jonathan Kaplan

41 min

In this episode of Life Sciences 360, we dive deep into the world of GLP-1 medications with Dr. Jonathan Kaplan. We discuss weight management, how these medications work, their impact beyond weight loss, and the ethical considerations surrounding their use. Dr. Kaplan shares his insights on the healthcare industry's evolving landscape, the economic implications, and why these medications are changing everything from cosmetic surgery to chronic disease management. Chapters: 00:00 Introduction   00:02 Dr. Jonathan Kaplan’s Background   00:16 Overview of GLP-1 Medications   00:25 The Significance of GLP-1s   00:35 Future FDA Approvals   00:51 Welcome to the Episode   01:12 Meet Dr. Jonathan Kaplan   01:19 Dr. Kaplan’s Journey into Weight Management   02:09 Early Days Before the GLP-1 Hype   02:30 Compounding Pharmacy and Medication Shortages   03:17 Success of the Weight Management Program   03:23 YouTube Subscriber Request   04:17 GLP-1 Mechanisms Explained   05:00 How GLP-1s Work in the Body   05:51 Historical Timeline of GLP-1 Medications   06:48 Semaglutide’s Evolution   07:23 The Rise of Ozempic and Wegovy   07:43 New Developments in Weight Management   08:54 Accidental Discoveries and Hormones   09:35 Significance of GLP-1 Discoveries   10:02 Medication Approval and Insurance Hurdles   10:43 Patient Expectations vs. Reality   12:09 Misconceptions About Weight Loss   12:51 Other Health Benefits Beyond Weight Loss   14:10 The Complex Psychology of Weight Loss   15:16 Importance of Diet and Exercise   16:10 How to Get Access to These Medications   18:02 Transparent Pricing Model   20:19 Maintenance and Subscription Options   22:04 Challenges with Insurance   23:21 Insurance Pitfalls and Complications   24:42 Speed of Access and Medication Availability   25:41 Ethical Considerations in Prescribing GLP-1s   27:28 Balancing Ethics and Accessibility   29:35 Broader Impact on Public Health and Economics   30:35 Transforming Healthcare Through Weight Management   32:12...

Astellas Pharma’s Approach to Cell and Gene Therapy

36 min

In this episode of LifeSciences 360, we dive into the fascinating world of cell and gene therapy manufacturing with Carlos Yuraszeck. With over 16 years of experience, Carlos shares his deep insights into the unique challenges, opportunities, and innovations in the field, offering a detailed look into what it takes to bring life-saving therapies to patients. We cover everything from the design of manufacturing facilities to the complexities of quality systems, patient-centric innovations, and the future of allogeneic therapies. If you're interested in the life sciences, cell and gene therapy, or just curious about cutting-edge advancements in medicine, this episode is for you! Chapters: 00:00 - Intro   00:02 - Understanding Cell and Gene Therapy Facilities   00:09 - Challenges in Cell Therapy Facility Design   00:26 - Automation in Manufacturing   00:42 - Balancing Quality, Cost, and Time   00:53 - Patient-Centric Manufacturing   01:21 - Guest Introduction: Carlos Yuraszeck   02:06 - Carlos’s Journey in Cell and Gene Therapy   03:21 - Unique Factors in Facility Design   04:14 - Making Facilities Operational   05:09 - Subscription Appeal   06:13 - Autologous vs. Allogeneic Cell Therapies Explained   08:13 - Adjusting Processes Based on Patient Variability   09:37 - Stem Cell Derived Therapies   10:39 - Biotech Companies: Autologous or Allogeneic?   12:07 - Strategic Decisions in Facility Design   14:50 - Phase-Appropriate Quality Systems   16:45 - Regulatory Flexibility and Urgency for Patients   18:08 - Change Control in Early vs. Late Phases   19:02 - Batch Records and Operator Judgment   20:27 - Training Focus for Different Phases   22:38 - Balancing Regulatory Requirements and Innovation   24:32 - Risk Assessment Based on Patient Needs   26:18 - The Potential of CAR T Therapies   28:05 - The Allogeneic Space and Future Prospects   31:00 - The Transformative Impact of Cell Therapy   32:22 - Carlos’s Career Lessons and Fear of the Unknown   34:45 - Closing Remar...

ISPE’s Role in Shaping the Future of mRNA and Personalized Medicine

34 min

In this episode of Life Sciences 360, we dive into the evolution of pharmaceutical and biotech manufacturing with our guest, Scott, a seasoned expert with nearly 30 years of experience working with industry giants like Novartis, Biogen, Thermo Fisher, and Merck. Scott shares insights on cell culture technology, mRNA vaccines, and the challenges and innovations in scaling biotech facilities. Discover the impact of collaboration and how organizations like the International Society for Pharmaceutical Engineering (ISPE) are transforming the landscape. Chapters : 00:00 - Introduction to Vaccine Technologies 00:14 - Importance of Collaboration in Pharma Manufacturing 00:22 - The Role of Technology Ecosystems 00:30 - Scott’s Experience with ISPE 00:46 - Motivation Behind Pharma & Biotech Careers 01:09 - Welcoming Scott to Life Sciences 360 01:19 - Scott’s Background & Industry Experience 01:45 - Integrating Technology in Pharmaceutical Facilities 01:59 - Scott’s Current Role & Unique Challenges 02:18 - Interview Kickoff: Scott’s Career Insights 03:11 - The Evolution of Drug Manufacturing 03:39 - Insights for Non-Pharma Audiences 03:59 - Changes in Vaccine Manufacturing Over the Years 04:40 - mRNA Technology and Its Impact 05:05 - Encouraging Viewers to Subscribe 05:59 - Driving Innovation in Manufacturing Facilities 07:01 - Challenges in Scaling New Therapies 08:17 - Overcoming Challenges in New Tech Implementation 09:03 - The Role of Technology Vendors 10:08 - Advancements in Manufacturing Technology 11:02 - Evolution of Biotech Processes 12:09 - Consulting in Cell and Gene Therapy 13:02 - The Infancy of Cell and Gene Therapy 13:23 - Introduction to SoulVentum 14:01 - Separation from 3M and Vision for SoulVentum 15:01 - Scott’s Role at SoulVentum 15:33 - Scott’s Contributions to ISPE 17:18 - Identifying Award-Winning Facilities 18:39 - ISPE Facility of the Year Criteria 20:18 - Global Reach of ISPE Submissions 21:41 - Geographical Insights Post-Pandemic 22:47 - The Role...

Balancing Leadership Roles in a High-Stakes Industry with Taggart McGurrin

30 min

Welcome to another episode of Life Sciences 360! Today, we're diving into the intricate world of life sciences leadership with a special guest who's worn nearly every hat in the industry—Taggart McGurrin. Starting in finance, transitioning to law, and tackling leadership roles across strategy, operations, and regulatory affairs, Taggart McGurrin brings a unique perspective on how to navigate the high-stakes environment of life sciences. In this episode, we cover: The Complexities of Life Sciences: Taggart McGurrin explains why this industry has more risk areas than most, from regulatory hurdles to financial pressures. Triple Threat in Leadership: Discover Taggart's approach to balancing “What you have, what you need, and what you want” for effective decision-making. Navigating the CFO/COO Role: Taggart shares insights on managing dual executive roles, emphasizing the importance of detail, resilience, and creative pragmatism. Overcoming Financial Hurdles: Insights on cash flow challenges and how proper planning and investor relations drive success. Unique Challenges in Life Sciences: The balancing act between meeting regulatory demands and fostering innovation. Whether you’re a leader in life sciences, considering a C-level role, or just curious about this industry, this episode is packed with practical insights! Chapters:  00:00 - Intro 01:00 - The Life Sciences Landscape 03:30 - Importance of Patient-Centric Leadership 10:00 - The Role of Detail in Executive Leadership 17:00 - Managing Financial Pressures in Life Sciences 22:00 - Navigating Regulatory Challenges 27:00 - Raising Capital in Life Sciences 29:00 - Final Takeaways If you’re looking to understand the unique challenges and leadership dynamics within life sciences, this is a must-watch! Don’t forget to subscribe for more content on leadership, innovation, and life sciences trends. 💡 Connect with Tagg McGurrin:  https://www.linkedin.com/in/taggartmcgurrin/ - Follow Life Sciences 360 on LinkedIn ...

Why Antimicrobial Resistance Is the Biggest Challenge in Public Health

41 min

In this episode of Life Sciences 360, host Harsh Thakkar sits down with Marc Sheetz, Associate Dean of Research at Midwestern University's College of Pharmacy, to discuss the growing concern of antimicrobial resistance and the field of pharmacometrics.  Marc sheds light on how pharmacometrics is shaping the future of medicine by using predictive models to personalize dosing, making drug treatments more effective while reducing toxicity. This episode dives deep into the intersection of pharmacometrics, AI, and machine learning, revealing how the future of patient care and treatment is rapidly evolving. Marc also shares insights from his current research in the infectious disease space, including his work with pediatric ICU patients. Chapters: 00:00 Introduction 00:03 Antibiotic Toxicity and Population Models 01:02 The Importance of Antibiotics and Public Health Challenges 01:22 Introduction to Pharmacometric Science 03:12 Using Data in Medicine for Future Predictions 06:01 Tailoring Drug Dosages for Individuals 09:36 The Global Variation in Drug Dosages and Challenges 14:44 The Future of Personalized Medicine and Precision Dosing 21:39 The Intersection of AI, Machine Learning, and Pharmacometrics 26:35 The Role of Technology in Medicine 30:01 How Dosing Software and AI Are Enhancing Patient Care 36:54 Innovation and Research Trends in Medicine - Connect with Marc Sheetz on Twitter:  (https://twitter.com/IDPharmacometrics)   - Learn more about Midwestern University:  (https://www.midwestern.edu)   - Follow Life Sciences 360 on LinkedIn  (https://www.linkedin.com/company/life-sciences-360) ---  Subscribe to our podcast for more insights on life sciences:  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 💬 Let us know in the comments: Did you know worms could be this powerful?   👍 Don't forget to hit Like and Subscribe for more fascinating interviews with leaders in life sciences! #Pharmacokinetics #Pharmacodynamics #Ant...

The Secret to Better Medications: Standardizing Pharmacogenomics (PGx) Testing

29 min

Imagine knowing how your body will respond to a medication before you even take it! In this episode, Harsh Thakkar interviews Sarah Rogers, co-founder and president of the American Society of Pharmacovigilance (ASP) and an Assistant Professor at Texas A&M. Together, they dive deep into the fascinating world of pharmacogenomics—how your genetic makeup affects your response to medications. They discuss the challenges of pharmacogenomic testing, real-world examples of adverse drug reactions, and the future of personalized medicine.  Chapters: 00:00 - Intro 00:16 - Breaking Down Pharmacogenomics 01:39 - Guest Introduction: Sarah Rogers   02:18 - Explaining Pharmacogenomics to a Child 03:24 - Sarah's Start in Pharmacogenomics   04:54 - The Power of Pharmacogenomics 07:00 - Pharmacogenomics Clinic at Texas A&M   09:02 - Challenges of Standardizing PGX Testing 11:14 - The Ideal Pharmacogenomics Workflow 13:39 - Real-World Example of PGX in Action 15:44 - Importance of Integrating PGX into EHR  20:24 - AI and Digital Twins in Pharmacogenomics 21:52 - Lessons Learned in Pharmacogenomics 24:46 - Looking to the Future of Personalized Medicine 28:18 - Final Takeaway   30:22 - Outro  Connect with Sarah Rogers: - LinkedIn: (https://www.linkedin.com/company/american-society-of-pharmacovigilance)   - STRIPE Initiative LinkedIn: (https://www.linkedin.com/company/stripe-pharmacogenomics)   - Twitter: (https://twitter.com/amsocietypharm)   - Newsletter signup for the American Society of Pharmacovigilance:  https://www.stopadr.org/ Here are links for some of the information that I mentioned during our meeting: - STRIPE Annual Meeting and Consensus Workshop - (https://www.usp.org/node/289416)  - Collaborative Communities: Addressing Health Care Challenges Together (https://www.fda.gov/about-fda/cdrh-strategic-priorities-and-updates/collaborative-communities-addressing-health-care-challenges-together) - Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Com...

Life Sciences Marketing Agency CEO on How to Combine Storytelling and Science for Impact

36 min

In this episode, Harsh Thakkar welcomes David Ormesher, CEO of CG Life, a leading marketing agency in the life sciences and pharmaceutical sectors. David shares over 30 years of experience in life science marketing and storytelling. From startups to large enterprises, CG Life helps companies blend complex science with compelling stories to resonate with patients, healthcare professionals, and investors. David discusses his entrepreneurial journey, how CG Life specializes in biopharmaceutical marketing, and key insights into building an agency that bridges the gap between science and storytelling. He also shares the strategic importance of focusing on the patient journey, how to scale marketing for companies of all sizes, and the role of digital platforms in the ever-evolving landscape of pharma and biotechnology marketing. Chapters: 00:00 - Introduction   00:09 - The Importance of Storytelling in Life Sciences   01:00 - David’s Journey into Life Science Marketing   02:00 - Starting CG Life and its Evolution   05:00 - Combining Science and Storytelling   08:00 - Challenges and Opportunities in Biopharma Marketing   10:00 - CG Life's Growth Strategy and Key Acquisitions   13:00 - Leveraging Social Media and Digital Platforms in Pharma   17:00 - Storytelling for Different Audiences: Patients, HCPs, and Investors   22:00 - Case Study: Terran Biosciences – Building Market Visibility   24:00 - Case Study: Novo Nordisk – Digital Customer Experience for HCPs   30:00 - Advice for Entrepreneurs Starting a Marketing Agency   34:00 - Lessons Learned from David’s Entrepreneurial Journey   36:00 - Building a Strong Team for Success   37:00 - Final Thoughts and Call to Action   Don’t forget to subscribe and share your thoughts in the comments! Let us know what topics or guests you want to see next. --- Links: Visit CG Life: (https://www.cglife.com)   Connect with David Ormesher on LinkedIn: (https://www.linkedin.com/in/davidormesher) - Subscribe to our podcast for more insig...

Could Worms REALLY Be the Key to Curing Autoimmune Diseases?

29 min

In this episode, we dive deep into a fascinating topic worm-derived therapeutics with our special guest Andrea, the founder and CEO of Holoclara. Did you know that autoimmune and allergic diseases were rare before the 1900s? What changed? Andrea shares groundbreaking insights into how worms, which have lived inside humans for millions of years, secrete molecules that could balance our immune system and help us tackle these diseases. From her early research days at Caltech to founding Holoclara, Andrea walks us through her journey, including: Chapters:   00:00 - The History of Autoimmune Diseases 01:24 - Why Watch This Video? 02:36 - Andrea’s Research Background 05:49 - The Turning Point: Entrepreneurship and Therapeutics 09:02 - Worms and Human Health: The Therapeutic Connection 11:32 - Worm Communication and Therapeutics 15:24 - The Industrial Revolution and Autoimmune Diseases 19:33 - How Worm-Derived Therapeutics Work 21:33 - Overcoming Challenges in Biotech 24:21 - The Future of Worm-Derived Therapeutics 25:48 - Studying Different Worm Species 26:57 - Life Outside Research 29:29 - Final Takeaway: Embracing Feedback and Opportunity Andrea also discusses the personal and scientific breakthroughs that led her to create Holoclara, a company dedicated to harnessing worm-derived molecules for modern medical solutions. Learn how roundworms evolved to produce tools that harmonize our immune system, and how these ancient organisms may hold the key to treating modern diseases. If you're intrigued by this incredible scientific journey and its implications for health, don't miss this episode! 🔗 Learn more about Holoclara: https://www.holoclara.com/  Linkedin: Andrea Choe, Co-Founder and CEO Holoclara https://www.linkedin.com/in/andreachoe/ Company page: https://www.linkedin.com/company/holoclara-inc/ - Subscribe to our podcast for more insights on life sciences:  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 💬 Let us know i...

How Amprion’s Test is Changing ALS, Dementia, and Parkinson’s Disease Diagnosis

37 min

Learn how misfolded proteins trigger cascading effects in the brain, leading to these devastating conditions, and how early detection can change the trajectory of treatment. Whether you’re curious about ALS, Parkinson’s, Dementia, or the role of molecular diagnostics. In this insightful episode, we dive deep into the world of neurodegenerative diseases, focusing on conditions like ALS, Parkinson's disease, Alzheimer's, and Dementia. Our guest, Russ Lebovitz, co-founder of Amprion, explains their groundbreaking work in detecting misfolded proteins, the primary culprits behind these diseases. From early diagnosis to understanding the role of technology and AI in healthcare, we explore how Amprion’s revolutionary diagnostic tools are shaping the future of brain health. Chapters: 00:00 - Introduction to the episode   00:13 - Amprion's unique approach to neurodegenerative diseases   00:40 - Misfolded proteins as the root cause   01:25 - Background of the guest, Russ Lebovitz   02:56 - Amprion's elevator pitch and core focus   03:59 - How Amprion detects misfolded proteins   05:57 - Misfolded proteins and their role in diseases   07:45 - The amplification process used by Amprion   09:27 - The causes of protein misfolding   12:29 - How Amprion's test works   14:05 - Early diagnosis through amplification   17:27 - Availability and expansion of Amprion's technology worldwide   21:03 - The role of AI in diagnosing neurodegenerative diseases   23:47 - Challenges in integrating AI into healthcare   27:17 - Predictions for future breakthroughs   32:35 - Collaboration between diagnostic tools, AI, and drug development   36:23 - Conclusion and closing remarks    🔗 Connect with Russ - Amprion website: (https://www.ampriondx.com) - Learn more about misfolded proteins and their role in brain diseases: (https://www.ampriondx.com/science) - Subscribe to our podcast for more insights on life sciences:  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3...

How Generative AI Finds Cures for Rare Diseases Faster

37 min

Welcome to episode 063 of Life Sciences 360. We dive deep into the groundbreaking role of AI in healthcare and life sciences with Shweta from Google Cloud. Learn how AI is accelerating drug discovery, enhancing patient care, and revolutionizing rare disease research. If you're passionate about the intersection of technology and health, this is a must-watch conversation! 🔗 Connect with Shweta on LinkedIn: https://www.linkedin.com/in/shwetasingh01/  📍 Explore more about Google Cloud: (https://cloud.google.com) Chapters: 00:00 Introduction   00:01 Using Generative AI for Drug Discovery and Molecular Structures   00:11 Synthetic Images from Histological Data for Rare Diseases   00:20 Bayer's AI for Regulatory Dossiers   00:38 Categories of AI Perspectives in Healthcare   01:00 Shweta’s AI Journey & Joining Google Cloud   02:01 Methodical Approach to AI in Healthcare   02:43 AI for Rare Diseases & Accelerating Drug Research   05:01 First Steps for Companies Embracing AI   06:51 Real-World AI Use Cases: Ginkgo Bioworks & Bayer   10:32 Potential Future Frameworks for AI in Regulatory Submissions   13:52 Challenges of Rare Diseases & AI Solutions   16:05 AI's Role in Accelerating Research & Repurposing Drugs   18:10 Broader Applications of AI in Life Sciences Beyond Rare Diseases   19:22 AI for Drafting Clinical Trials & Patents   21:27 Addressing Concerns of AI in Healthcare: Ethics, Safety, and Bias   24:46 Human-in-the-Loop: The Key to Safe AI Use in Medicine   30:39 The Future of AI in Healthcare: Democratizing Access & Proactive Care   37:06 Outro & How to Connect with Shweta --- Links: *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ ) *Listen to this episode on the go!  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthcare trends. 💬 Comment below any questions you have. Have you implemented this into your operations yet?  🔔 Subscribe...

3 Steps to Avoid Burnout and Thrive in Biopharma, from a Global Expert

35 min

Welcome to episode 062 of Life Sciences 360. In this episode, we dive into an engaging conversation with Tom, a seasoned consultant, on how to recognize the early signs of burnout, foster a healthy and innovative work environment, and implement agility in regulated industries. Tom shares practical strategies for leaders and consultants alike to maintain performance without compromising mental well-being. Whether you're a business leader, consultant, or anyone looking to improve work-life balance, this video is packed with actionable advice! Chapters: 00:00 – Introduction   00:34 – Life as a Consultant: What It’s Really Like   01:00 – Burnout in Consulting vs. 9-to-5 Jobs   02:06 – Recognizing Early Signs of Burnout   03:56 – Overpromising and Work-Life Balance   04:31 – 3 Key Strategies to Prevent Burnout   05:52 – Managing Priorities and Influencing Decisions   09:55 – The Sandbox Approach to Innovation   12:02 – Innovation in Regulated Industries   14:30 – Encouraging Employee Experimentation   17:39 – Real-World Examples of Innovation Success   18:20 – Leadership Qualities That Promote Innovation   21:50 – Systems for Capturing and Reviewing Ideas   26:03 – Challenges of Implementing Agile in Regulated Industries   29:00 – Countering Opposition to Agile   33:01 – The Best Part of Consulting: Tom’s Take   34:48 – How to Connect with Tom   35:17 – Final Thoughts on Preventing Burnout Connect with Tom: LinkedIn: https://www.linkedin.com/in/tom-siebeneicher/   Spotify: https://open.spotify.com/episode/0aXLVMPZtFh79TKle9aN9y?si=4Xswz8zGTeKnkkogqB0BTg   YouTube: https://www.youtube.com/playlist?list=PL3RKCnY-ES1kNaNP7WnQ37uiweOEbjB7O Links: *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ ) *Listen to this episode on the go!  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthcare trends. 💬 Comment below any questions you have. Have you impl...

How Samsung Biologics Achieved 16 Top Pharma Partnerships as a CDMO

43 min

Welcome to episode 061 of Life Sciences 360. In this episode of Life Sciences 360, host Harsh Thakkar sits down with Kevin Sharp, Senior Vice President and Head of Global Sales at Samsung Biologics. They dive deep into the evolving CDMO industry, the importance of agility, innovation, and the strategic growth pillars that are driving success at Samsung Biologics. Kevin shares his journey from government roles to life sciences, discusses the rapid advancements in ADCs, and explores how emerging technologies like AI are reshaping the industry. Chapters: 00:00 - Introduction   00:02 - Overcoming Roadblocks in the Industry   00:10 - Flexibility and Agility in Implementation   00:18 - Innovating Through Challenges   00:24 - The Mission of Life Sciences and Pharma   00:52 - The Speed Factor in Pharma Development   01:26 - Introduction to Kevin Sharp and Samsung Biologics   02:00 - Kevin Sharp's Career Journey to Life Sciences   03:29 - Transition from Pharma to CDMO Space   05:29 - The Rapid Growth of the CDMO Industry   07:14 - Key Challenges in Transitioning to a CDMO Role   09:22 - The Boom of CDMOs and Their Impact   11:32 - Regulatory Challenges and CDMO Expertise   13:48 - Strategic Partnerships with Top Pharma Companies   15:59 - The Importance of Diversification and Capability Growth   18:25 - Building Long-Term Partnerships with CDMOs   22:04 - Adapting to Roadblocks with Agility   23:59 - ADC Market Insights and Samsung Biologics’ Strategy   28:24 - The Future of Life Sciences: New Modalities and Technologies   30:27 - Leveraging Emerging Technologies like AI in CDMOs   34:52 - Leadership and Operational Excellence in Life Sciences   39:20 - Working at Samsung Biologics   41:17 - Final Thoughts and How to Connect with Kevin Sharp Connect with Kevin Sharp: Kevin's LinkedIn: (https://www.linkedin.com/in/kevinsharp)   Samsung Biologics: (https://www.samsungbiologics.com/) Don’t forget to like, share, and subscribe for more insightful conversations on achievin...

Why the Top 1% are lonely- insights from Dr. Robyn Odegaard

36 min

Welcome to episode 060 of Life Sciences 360. In this episode of Life Sciences 360, host Harsh Thakkar sits down with Dr. Robin Odegaard, a high-performance business psychologist and professional confidant, to discuss the hidden struggles that come with success. They dive deep into topics like imposter syndrome, self-sabotage, complex priorities, and the loneliness that often accompanies high achievement. Dr. Robin shares actionable strategies and insights from her extensive work with lawyers, biotech CEOs, neurosurgeons, and more. Chapters: 00:00 - Introduction   00:33 - The Voice in Your Head & Head Trash   01:29 - Dr. Robin’s Journey into High-Performance Psychology   02:48 - Understanding Self-Sabotage and How It Manifests   05:10 - The Loneliness of Success: Why It’s “Lonely at the Top”   07:23 - Techniques to Recognize and Combat Self-Sabotage   11:22 - Managing Complex Priorities with the “Foresting Project”   15:48 - Time Audits & Delegation for Effective Time Management   18:41 - The Challenge of Letting Go for High Performers   20:58 - Working with Diverse Clients: From Athletes to CEOs   23:03 - Emotional State Management for Better Communication   27:28 - The Isolation of Success & Who High Achievers Talk To   33:47 - Final Thoughts & Advice for Listeners   35:58 - Conclusion Connect with Dr. Robin Odegaard: - Website: (https://www.mentalmacgyver.com)   - LinkedIn: (https://www.linkedin.com/in/robinodegaard)   - YouTube: (https://www.youtube.com/@DrRobin) Watch Next:  Take Out the Head Trash | How to Fight the Demons Keeping You Awake at 3 a.m (https://youtu.be/Kx12TTCoojg?si=BDsG4KLZOVMO71HW) Don’t forget to like, share, and subscribe for more insightful conversations on achieving success in life sciences and beyond! --- Links: *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ ) *Listen to this episode on the go!  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if yo...

The Science Behind Tome’s Programmable Genomic Integration Technology with CSO John Finn

43 min

Welcome to episode 059 of Life Sciences 360. In this episode of Life Sciences 360, Harsh Thakkar is joined by John Finn, Chief Scientific Officer at Tome Biosciences. John shares his inspiring journey of overcoming challenges, like his stutter, while making groundbreaking strides in gene therapy. They dive deep into Tome’s unique technology, PGI (Programmable Genomic Integration), which is revolutionizing how large-scale gene insertions are done with pinpoint accuracy. Learn how Tome Biosciences is leading the charge in curing genetic disorders and advancing cell therapy with cutting-edge science. Chapters: 00:00 - Introduction to the Episode 00:29 - The Vision Behind Gene Therapy 01:13 - John’s Journey and Challenges with Stuttering 03:14 - How Stuttering Shaped John's Career in Science 05:43 - Introduction to Tome Biosciences 07:02 - The Origins of Tome and Founding Vision 09:49 - Why Large-Scale Gene Editing Matters 14:12 - How Tome's PGI Technology Works 20:29 - What Sets Tome Apart in Gene Therapy 24:31 - Future Milestones for Tome Biosciences 30:49 - Overcoming Challenges in Genomic Integration 36:47 - The Power of Team Culture at Tome Biosciences 40:20 - Advice for Aspiring Scientists and Entrepreneurs 42:52 - Where to Connect with John Finn and Learn More About Tome - Follow John Finn:  *Linkedin - ( https://www.linkedin.com/in/jonathan-john-finn-8b3bb23/ )  *Tome Bio Linkedin -  ( https://www.linkedin.com/company/tome-biosciences/ )  * Tome Bio Website- ( https://tome.bio/ ) --- Links: *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ ) *Listen to this episode on the go!  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthcare trends. 💬 Comment below any questions you have. Have you implemented this into your operations yet?  🔔 Subscribe to our channel @lifesciences360 for more expert interviews about the rapidly evolving world o...

Inside the Lab: How Singota Solutions Leads in Early-Stage Pharma Development

32 min

Welcome to episode 058 of Life Sciences 360. In this insightful episode of Life Sciences 360, hosted by Harsh Thakkar, we explore the dynamic world of Contract Development and Manufacturing Organizations (CDMOs) with Ryan Memmer, Manager of Quality Control and Product Development at Singota Solutions. Ryan shares his journey from working at large pharmaceutical companies to leading a growing team at Singota, a CDMO focused on phase one drug development. He provides a behind-the-scenes look at the challenges and opportunities in this fast-paced environment, and how Singota is uniquely positioned to support early-stage pharmaceutical companies. Chapters: 00:00 - Introduction: Ryan Memmer’s background and role at Singota. 01:10 - Career Journey: Transition from large pharma to a smaller CDMO. 03:18 - Challenges in CDMO Culture: Overcoming fast-paced industry challenges. 06:59 - Knowledge Sharing and Trust: Building trust in early phase work. 08:03 - Singota's Unique Strengths: What sets Singota apart in the CDMO space. 11:32 - Importance of Diverse Backgrounds: Value of diverse skill sets within the team. 13:04 - Client Collaboration: Singota’s approach to custom client solutions. 17:25 - Broad Client Portfolio: Overview of Singota's diverse client base. 20:03 - Preparing for Commercialization: Adapting to phase three and commercial standards. 24:19 - Singota’s Global Expansion: Expanding operations into international markets. 25:56 - Advice for Aspiring Scientists: Tips for those starting out in QC or product development. 28:22 - Continuous Learning: Emphasizing the importance of cross-functional learning. 31:11 - Closing Thoughts: Final thoughts from Ryan Memmer and how to connect. - Follow Ryan Memmer: - Singota Solutions Official Website: (https://singota.com/) - Follow Ryan Memmer on LinkedIn: (https://www.linkedin.com/in/memmer-ryan/) Key Takeaways: - Understanding the unique challenges of working in a CDMO environment. - The importance of knowledge sharing...

Bioidentical Hormone Replacement: A Deep Dive with Dr. Greg Brannon

38 min

Welcome to episode 057 of Life Sciences 360. In this special episode of Life Sciences 360, hosted by Harsh Thakkar, we dive into the fascinating world of bioidentical hormone replacement therapy (BHRT) with Dr. Greg Brannon, Medical Director and Founder of Optimalbio. Celebrating National Men's Health Education and Awareness Month, Dr. Brannon shares his expertise on the benefits of BHRT, the science behind hormone therapy, and the insights from his Amazon bestseller book, "Restore." Chapters: 00:01 - Introduction: Discussing the importance of health education. 00:37 - The significance of hormone health. 01:30 - The journey behind Dr. Brannon's book "Restore." 02:52 - The role of testosterone and hormones in overall health. 03:43 - Dr. Brannon's medical background and shift to hormone therapy. 05:20 - Understanding bioidentical hormone replacement therapy (BHRT). 06:20 - The science behind hormone therapy and its impact on chronic diseases. 08:19 - Broader implications of hormone imbalances in society. 09:41 - Practical advice for optimizing hormone levels. 10:42 - The impact of modern lifestyle on hormone health. 12:09 - Hormone therapy in practice and success stories. 15:11 - The future of Optimalbio and its expansion plans. 16:19 - Closing remarks and contact information for further learning. - Follow Dr. Greg Brannon:  *YouTube:(https://www.youtube.com/channel/UCRWEkzCUh_CHIBGB5dae5rw)  *Instagram - (https://www.instagram.com/optimalbio/)  *TikTok - (https://www.tiktok.com/@optimobio)  *Linkedin - (https://www.linkedin.com/company/optimal-bio/)  * OptimoBio Website- (https://optimalbio.com/) Key Takeaways: - Understanding the crucial role of hormones in maintaining overall health. - The benefits of bioidentical hormone replacement therapy (BHRT). - Practical tips for maintaining optimal hormone levels through lifestyle changes. - Success stories from patients who have benefited from hormone therapy. --- Links: *Harsh Thakkar LinkedIn ( https://www.linkedin...

How Green Elephant Biotech is making labs more sustainable with Joel Eichmann

38 min

Welcome to episode 056 of Life Sciences 360. Welcome to another episode of Life Sciences 360! In this episode, Harsh Thakkar is joined by Joel Eichmann, co-founder and managing director of Green Elephant Biotech. Green Elephant Biotech is a trailblazer in the biotech industry, focusing on sustainability and using plant-based materials to create innovative products. Joel shares the fascinating journey of how Green Elephant Biotech started, the challenges they faced, and the future of sustainable biotech. Chapters: 00:00 - Introduction 01:23 - Welcoming Joel Eichmann 02:39 - Origins of Green Elephant Biotech 05:15 - From Concept to Commercial Product 07:30 - Early Challenges and Strategies 10:02 - Advice for Aspiring Biotech Entrepreneurs 12:33 - Incorporating Sustainability 15:01 - Hiring and Building the Team 18:37 - Understanding the Life Sciences Industry 21:19 - Balancing Innovation and Sustainability 24:05 - Industry Challenges and Opportunities 27:34 - Generating New Product Ideas 30:13 - Recognition and Awards 31:31 - Long-term Goals and Automation 34:28 - The Future of Automation in Biotech 36:06 - Where to Learn More About Green Elephant Biotech 37:44 - Final Thoughts on Sustainability Connect with Joel Eichmann - Green Elephant Biotech: (https://www.greenelephantbiotech.com/) Joel Eichmann: (https://www.linkedin.com/in/joel-eichmann/) Harsh Thakkar: (https://www.linkedin.com/in/harshvthakkar/) *Listen to this episode on the go!  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthcare trends. 💬 Comment below any questions you have on Generative AI. Have you implemented this into your operations yet?  🔔 Subscribe to our channel @lifesciences360 for more expert interviews about the rapidly evolving world of life sciences. 📲 Follow us on social media to keep up with the latest news and discussions in the biotech and pharmaceutical sectors. #LifeScien...

The Future of mRNA Therapies with Dr. Kate Broderick

34 min

Welcome to episode 055 of Life Sciences 360. In this episode of Life Sciences 360! In this episode, Harsh sits down with Dr. Kate Broderick, Chief Innovation Officer at Maravai Life Sciences. Dr. Broderick shares her journey from academia to leading innovation in the biotech industry, discusses the pivotal role of Clean Cap technology in COVID-19 vaccines, and explores the future applications of mRNA. Learn about the collaborative spirit at Maravai and the exciting developments in genomic medicine, personalized cancer vaccines, and more.  Join Harsh Thakkar in an insightful conversation with Dr. Kate Broderick, the Chief Innovation Officer at Maravai Life Sciences. Discover the future of mRNA, the role of Clean Cap technology in COVID-19 vaccines, and the innovative work happening at Maravai and its subsidiaries. Chapters: 00:00 - Introduction 00:03 - Dr. Kate Broderick's Career Background 00:38 - Overview of Maravai Life Sciences 01:22 - Starting in Life Sciences and Career Journey 03:17 - Role of Chief Innovation Officer 04:02 - Turning Ideas into Innovations 05:22 - Blending Research, Development, and Leadership 07:40 - Working at Maravai and Cross-functional Leadership 08:05 - Clean Cap Technology and its Impact 09:15 - Maravai’s Business Units and Synergies 10:25 - Clean Cap in COVID Vaccines 11:48 - Future Applications of mRNA 13:31 - Overcoming Challenges with mRNA 15:09 - Improving Stability and Targeting Specific Cells 17:49 - Importance of Collaboration in Science 19:25 - Maravai's Approach to Partnerships and Collaborations 23:12 - New mRNA Manufacturing Facility 25:22 - Functional Segmentation of Facilities 27:35 - Recognition as a Top Biotech Executive 29:46 - Exciting Areas in Life Sciences for the Future 31:50 - Potential of CRISPR and Base Editing 33:19 - Closing Remarks and Contact Information Connect with Dr. Kate Broderick: - Kate Broderick (https://www.linkedin.com/in/katebroderick) - Maravai Life Sciences: (https://www.maravai.com) - TriLin...

Vector Labs CEO Lisa Sellers on Innovation, Leadership, and Mentorship

42 min

Welcome to episode 054 of Life Sciences 360. In this episode of Life Science 360 ,Today, we are thrilled to have Lisa Sellers, the CEO of Vector Labs, as our special guest. Lisa shares her incredible journey from working at big names like Thermo Fisher and 10x Genomics to leading Vector Labs, a trusted manufacturer of reagents and critical components in the life sciences sector. In this episode, we dive deep into: - Lisa's transition from being an industry professional to becoming a CEO - The unique challenges and benefits of working in smaller companies - Vector Labs' strategic acquisitions and mergers to expand their product portfolio - The impact of Vector Labs in the pharmaceutical, diagnostic, and academic sectors - Lisa's passion for mentorship and her efforts to inspire the next generation in STEM fields Chapters : 00:00 - Introduction 00:41 - Welcome Lisa Sellers 01:12 - Lisa’s Career Journey 02:37 - Transition to CEO 05:00 - Comparing Big Companies to Smaller Companies 09:28 - Vector Labs’ Product and Service Overview 14:25 - Recent Acquisitions and Expansions 17:20 - Role of Private Equity in Vector Labs 20:28 - Challenges in Protein and Glycan Detection 23:54 - Vector Labs’ Diverse Customer Base 26:59 - Managing Priorities and Resources 29:00 - Vision for Vector Labs in the Next 5 Years 32:39 - Lisa’s Mentorship and Community Involvement 37:17 - Key Leadership Qualities in STEM 41:28 - Final Thoughts and Closing Stay tuned and don't forget to subscribe for more in-depth conversations with leading scientists and innovators in the life sciences field! -----  Links: *Lisa Sellers: (https://www.linkedin.com/in/lisa-sellers/) *Vector Labs: (https://www.linkedin.com/company/vector-laboratories/) *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ ) *Listen to this episode on the go!  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthc...

Scientist on Epigenetic Tuning and Future Therapies at Tune Therapeutics

36 min

Welcome to episode 053 of Life Sciences 360. In this episode of Life Science 360, our host Harsh Thakkar sits down with Brian Cosgrove, Principal Scientist at Tune Therapeutics. Brian dives deep into the fascinating world of epigenetics and its role in developing therapies for complex diseases. He shares insights on how Tune Therapeutics is leveraging the power of the epigenome to create innovative treatments, particularly focusing on their work with hepatitis B and the promising potential of their tempo platform. Chapters: 00:00 - Introduction 00:02 - Understanding Cell Differentiation and Gene Regulation 00:37 - Welcome Brian Cosgrove from Tune Therapeutics 01:15 - Brian's Transition from Duke University to Tune Therapeutics 02:03 - The Basics of Epigenetic Tuning 02:38 - How Epigenetics Determines Cell Function 03:55 - The Role of the Epigenome in Gene Expression 05:06 - The Complexity of the Human Body and Scientific Research 06:12 - Deep Dive into Hepatitis B (HBV) 06:57 - Current Treatments for Chronic Hepatitis B 08:32 - The Unmet Need in Hepatitis B Treatment 09:09 - Brian's Career Path and Decision to Join Tune Therapeutics 12:03 - Growth and Evolution of Tune Therapeutics 15:25 - Challenges and Rewards of Joining an Early-Stage Company 17:49 - Introduction to the Tempo Platform 19:04 - How Tempo Platform Works with HBV 20:32 - Epigenetic Regulation of HBV 23:20 - Future Applications of Epigenetic Tuning 24:38 - Timeline for Tune 401 Clinical Trials 26:08 - Anticipated Challenges and Solutions 27:20 - Partnering for Manufacturing and Delivery 28:32 - The Broader Field of Epigenetic Therapies 30:21 - Potential Global Impact of Epigenetic Therapies 32:12 - The Most Rewarding Part of Brian's Work 33:01 - The Personal Side of Working in Life Sciences 35:10 - Final Thoughts and Future Outlook for Tune Therapeutics 36:09 - Closing Remarks and How to Connect with Brian Stay tuned and don't forget to subscribe for more in-depth conversations with leading scient...

Breaking Down Barriers in Psychedelic Drug Development

42 min

Welcome to episode 052 of Life Sciences 360. In this episode, of Life Sciences as we dive into the fascinating world of psychedelic therapeutics with Dr. Sam Clark, the Chief Executive Officer of Terran Biosciences. Dr. Clark shares his journey of founding Terran Biosciences, motivated by the need for better treatment options for psychiatric and neurological disorders. Discover how Terran Biosciences is leveraging a tech company structure to accelerate drug development, utilizing AI in imaging, and pioneering innovative prodrugs.  Learn about the company’s groundbreaking work in developing psychedelics without hallucinations and their mission to make these therapies affordable and accessible to patients.  Subscribe for more insightful conversations with leaders in the biotech and life sciences industries! Chapters: 00:00 - Introduction 00:12 - Dr. Sam Clark's Motivation and Background 01:00 - Founding Terran Biosciences 01:35 - Challenges in Psychiatric and Neurological Treatment Development 02:55 - Innovating with a Tech Company Structure 03:18 - Use of AI and Drug Development Strategies 04:18 - Slow Translation of Research to Therapies 05:50 - Development of New Prodrugs 07:12 - Explanation of Prodrugs 08:49 - Terran's Lead Assets for Psychotic Disorders 10:16 - Creating Long-Acting Prodrugs 12:16 - Addressing Regulatory Hurdles in Psychedelic Research 14:20 - Pipeline Overview and Future Plans 16:13 - Importance of Collaboration in Psychedelic Research 17:58 - The Rise of Big Pharma Interest in Neuroscience 20:14 - Addressing Stigma Around Psychedelics 23:02 - Overcoming Regulatory Challenges 26:31 - Trends in Psychedelic Funding 31:48 - Making Medications More Accessible 37:00 - Impact of Psychedelic Approvals on the Industry 38:20 - Focus on Patient-Centric Approaches 41:11 - Final Thoughts and Future Announcements Follow Terran Biosciences on LinkedIn and X, and visit their website for the latest updates and announcements.  ----- Links: - [Terran Bios...

From Genes to Treatments: Howard McLeod on Precision Medicine

41 min

Welcome to episode 051 of Life Sciences 360. We welcome Howard McLeod, a distinguished expert in precision medicine and pharmacogenomics. Howard shares his profound journey into the world of personalized medicine, emphasizing the significant impact of individualized treatments on cancer patients. From groundbreaking gene discoveries to advising cutting-edge biotech companies, Howard's work underscores the value of targeted therapies and their potential to transform patient outcomes. Howard also discusses his current roles, including his position as the Center Director for Precision Medicine and Functional Genomics at Utah Tech and his advisory role in several companies. He shares insights into exciting projects aimed at improving drug response predictions and mental health treatments for university students through pharmacogenomics. Chapters 00:00 - Introduction and Guest Welcome 01:00 - The Importance of Experimental Therapies 02:00 - Career Inspiration and Key Moments 04:00 - Mentors and Lessons Learned 06:00 - Practical Applications of Research 08:00 - Staying Grounded in Patient Care 10:00 - Current Roles and Projects 12:00 - Addressing Mental Health in Students 14:00 - Integrating Technology in Medicine 18:00 - Simplifying Complex Medical Information 22:00 - Reflections on Technological Advancements 26:00 - Embracing Change and New Challenges 30:00 - Final Thoughts and Future Outlook 36:00 - Closing Remarks and Contact Information This episode is a treasure trove of insights for anyone interested in precision medicine, pharmacogenomics, and the future of healthcare. Don't miss Howard McLeod's inspiring journey and the valuable lessons he shares! ----- Links: *Dr. Howard McLeod LinkedIn ( https://www.linkedin.com/in/howard-mcleod-90866a12/) *Harsh Thakkar LinkedIn (https://www.linkedin.com/in/harshvthakkar/) *Listen to this episode on the go! 🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you...

Tony Martignetti on Inspired Leadership, Flashpoints, and Divergent Thinking

42 min

Welcome to episode 050 of Life Sciences 360. In this episode, Harsh Thakkar chats with Tony Martignetti, a top leadership development voice on LinkedIn and an advisor to numerous tech and life sciences executives. Tony shares his insights on inspired leadership, the importance of investing in people, and how to unlock potential within teams. They also discuss the concept of flashpoints in both personal and organizational contexts and the value of embracing divergent thinking in the workplace. Chapters: 00:00 Introduction to Tony Martignetti and Leadership Development 01:04 Advocating for Inspired Leadership 02:23 Influences: Henry Tamir and “No Rules, Rules” Book 04:37 Investing in People: Beyond Pedigree 06:19 Authentic Leadership: Bringing Your Whole Self to Work 09:40 The Core Model: Encouraging Authenticity in Teams 11:33 Identifying and Aligning Personal and Organizational Flashpoints 13:04 Overcoming Barriers: Personal Stories and Career Challenges 16:13 Flashpoints in Organizations: Examples and Insights 19:34 Embracing Divergent Thinking for Innovation 25:30 Convergent Hearts: Building Connection and Understanding 30:46 Practical Tips for Leaders to Foster Innovation and Growth 35:21 Specialist vs. Generalist: Expanding Skills and Knowledge 39:36 Key Takeaways: Expanding Vision and Narrowing Focus ----- Links: *Tony Martignetti LinkedIn (https://www.linkedin.com/in/tonymartignetti1/) *Tony Martignetti Website (https://ipurposepartners.com/) *Harsh Thakkar LinkedIn (https://www.linkedin.com/in/harshvthakkar/) *Listen to this episode on the go! 🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthcare trends. For transcripts, check out the podcast website - www.lifesciencespod.com

Understanding Drug Pricing and the Impact of the Inflation Reduction Act with Jesse Mendelsohn

39 min

Welcome to episode 049 of Life Sciences 360. In this episode of Life Sciences 360, host Harsh Thakkar welcomes Jesse Mendelsohn, Senior Vice President at Model N. Jesse delves into the intricacies of revenue optimization and compliance within the pharmaceutical industry. He shares insights on how Model N's platform aids pharmaceutical companies in navigating complex pricing, regulatory challenges, and government negotiations. Chapters : 0:00 - Introduction 1:30 - Welcoming Jesse Mendelsohn 2:00 - Jesse's Journey with Model N 6:00 - Evolution of Pharma Pricing and Compliance 8:30 - Challenges in Commercial Contracting 12:00 - Regulatory Side of Pharma Pricing 14:30 - Impact of Government as a Major Drug Purchaser 16:00 - Inflation Reduction Act Overview 19:00 - Medicare's Right to Negotiate Drug Prices 21:00 - Aftershocks of the Inflation Reduction Act 23:30 - Key Takeaways for Pharma Executives 26:00 - Impact on Drug Development Strategy 28:00 - Generics and Biosimilars Market Impact 30:30 - Positive Outcomes of the Inflation Reduction Act 32:00 - What's Next for Model N 36:00 - Importance of Accurate Data in Pricing 38:30 - Closing Remarks and Connect with Jesse ----- Links: * Jesse Mendelsohn LinkedIn (https://www.linkedin.com/in/jessedm/) * Model N LinkedIn (https://www.linkedin.com/company/modeln/) * Model N website (https://www.modeln.com/) *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/  ) *Listen to this episode on the go! 🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthcare trends. For transcripts, check out the podcast website - www.lifesciencespod.com

How DoseMeRx is Transforming Patient Care

33 min

Welcome to episode 048 of Life Sciences 360. In this episode, Sharmeen discuss the current one-size-fits-all approach in healthcare and the need for precision dosing. Sharmeen explains how DoseMe platform simplifies complex dosing methods at the bedside, benefiting both clinicians and patients. Sharmeen also touch on the integration with electronic health records and the use of real-world data to improve dosing. Shownotes : 00:00 Introduction 02:58 User Demographics 04:42 Integration with EHR 10:20 Therapeutic Areas 14:00 Bayesian Method 16:20 Real-time Data 20:20 Nerd Out on the Topic 25:00 AUC-guided Dosing 29:00 Implementation Process ----- Links: * Sharmeen Roy LinkedIn (https://www.linkedin.com/in/sharmeenroy/) * DoseMe LinkedIn (https://www.linkedin.com/company/doseme-pty-ltd/ ) * DoseMe website (https://doseme-rx.com/) *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/  ) *Listen to this episode on the go! 🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthcare trends. 💬 Comment below any questions you have on Generative AI. Have you implemented this into your operations yet?  🔔 Subscribe to our channel @lifesciences360 for more expert interviews about the rapidly evolving world of life sciences. 📲 Follow us on social media to keep up with the latest news and discussions in the biotech and pharmaceutical sectors. #PrecisionDosing #BayesianDosing #HealthcareInnovation #DoseMeRx #Pharmacology #ClinicalTrials #IndividualizedMedicine #BayesianMethods #HarshThakkar #SharmeenRoy For transcripts, check out the podcast website - www.lifesciencespod.com

How InVision helps you make drug development decisions? #lifesciences

40 min

Welcome to episode 047 of Life Sciences 360. In this video, We discuss the importance of using AI in decision making in the life sciences industry. Ben  highlight the need for evidence-based decision making and the challenges of finding relevant information in a sea of data. Ben introduce InVision, a platform that helps biotech and pharma companies stay informed about clinical trials and changes in the industry.  Watch the video to learn how AI can assist in making informed decisions in the life sciences field. Chapters : 00:00 - Introduction 00:24 - AI in Decision-Making 00:45 - Welcome and Guest Introduction 01:00 - InThought Research and Infernesis 02:00 - Challenges in Clinical Trials 03:40 - InVision Technology Platform 06:36 - AI Integration in InVision 08:22 - Machine Learning and Natural Language Processing 13:20 - Case Study: Clinical Trial Data Analysis 17:56 - Privacy and Regulation in Healthcare 19:34 - AI and Job Security 24:21 -Practical Applications of AI 26:16 - Spire Bioadvisors 29:40 - Trends in Biotech and Drug Development 32:58 - Future of AI in Healthcare 37:28 - Ben's Personal Insights 39:12 - Closing Thoughts -----  Links: * Ben Weintraub LinkedIn (https://www.linkedin.com/in/ben-weintraub-0566389/) * inThought Research LinkedIn (https://www.linkedin.com/company/inthought-research/ ) * inThought Research website (https://inthought.com/) *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/  ) *Listen to this episode on the go!  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr 👍 Like this video if you enjoy diving deep into the latest healthcare trends. 💬 Comment below any questions you have on Generative AI. Have you implemented this into your operations yet?  🔔 Subscribe to our channel @lifesciences360 for more expert interviews about the rapidly evolving world of life sciences. 📲 Follow us on social media to keep up with the latest news and discussions in the biotech and pharmace...

How CTMC is Changing Medicine Manufacturing

37 min

Welcome to episode 046 of Life Sciences 360. On this episode, Harsh discuss the intersection of luck and preparation in finding opportunities, particularly in the field of cell therapy. Harsh share insights from his conversation with Dr. Jason Bock, founder and CEO of CTMC, about the advancements and challenges in autologous cell therapies. We delve into topics such as manufacturing, strategy formation, and the impact of cell therapy on oncology.  This episode provides valuable information for anyone interested in the field and invites viewers to explore the possibilities of this groundbreaking technology. Show notes: 00:00 Introduction 02:40 Autologous Cell Therapies 04:40 Formation of CTMC 08:40 Recognition and Impact 11:48 Challenges in Cell Therapy Manufacturing 15:00 Acquisition of a Facility 17:20 Unexpected Growth 21:49 Houston's Support for Multi-Center Trials 27:52 Conceptualizing Virtual Manufacturing 34:20 Maintaining Focus and Vision -----  Links: * Jason Bock LinkedIn ( https://www.linkedin.com/in/jason-b-bock/ ) * CTMC LinkedIn (https://www.linkedin.com/company/celltherapymanufacturingcenter/) *CTMC website (https://ctmc.com/) *Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/) *Listen to this episode on the go!  🍎Apple podcast: https://apple.co/3RXPoS1 🟩 Spotify podcast: https://spoti.fi/3EbDZbr -----  #Biotech #celltherapy  #MDAnderson #LifeSciences #CellManufacturing #CancerResearch #AdvancedTherapies #BiotechIndustry #MedicalResearch #InnovativeTherapies #BiotechPartnerships #BiotechCareer #Biopharmaceuticals #DigitalQuality #BiotechLeadership #IndustrialManufacturing #healthcareinnovation #MedicineMakers #Biologics #ClinicalResearch #CancerTreatment For transcripts, check out the podcast website - www.lifesciencespod.com

AI in Life Sciences: Should You Follow This Trend?

41 min

Welcome to episode 045 of Life Sciences 360. On this episode, Nagesh Nama and his team at XLM talk on why Gen.AI is essential in the software test world and share examples of its use in various industries, particularly in life sciences and manufacturing. They address the challenges faced by companies in adopting AI and provide solutions for integrating AI into existing systems. Harsh and his guests discuss how AI can improve productivity, enhance quality assurance processes, and enable proactive decision-making. The conversation emphasizes the importance of having an AI strategy and encourages SMBs to embrace AI to gain a competitive advantage. ----- Links: * Nagesh Nama LinkedIn * xLM LinkedIn *xLM website *Harsh Thakkar LinkedIn *Would you rather watch this episode? Click here for the YouTube episode. 👍 Like this video if you enjoy diving deep into the latest healthcare trends. 💬 Comment any questions you have on Generative AI. Have you implemented this into your operations yet? 🔔 Subscribe to our channel Life Sciences 360 for more expert interviews about the rapidly evolving world of life sciences. 📲 Follow us on social media to keep up with the latest news and discussions in the biotech and pharmaceutical sectors. -----  Show Notes: (0:00) Human vs. AI Diagnosis (4:40) Using AI to Automate Clinical Trial Management Systems (8:18) Challenges of AI adoption & Data Integrity  (13:55) Affordable AI Validation Services for SMBs (17:55) New Companies Add AI Features, Chat GPT Stays Ahead (21:58) How To Increase Productivity & Improve Compliance  (26:44) XLM's AI Powered Platform (30:45) AI in Pharma  (34:57) Using AI for Supply Chain Management For transcripts, check out the podcast website - www.lifesciencespod.com

The NASA Scientist Who Changed Cancer Diagnostics Forever

37 min

Dr. Arnon Chait, CEO of Cleveland Diagnostics, discusses his transition from NASA to the healthcare innovation space and the development of cancer diagnostics. Dr. Chait emphasizes the importance of using diagnostic advancements to strike a balance between over-screening and under-treating, particularly in the workup of cancer after failed screenings.  He discusses the development of their innovative prostate cancer diagnostic test. In Episode 044 of Life Sciences 360, Harsh and Arnon also emphasize the importance of asking the right questions in scientific research and the need for simple and actionable diagnostic tools in healthcare. They advise individuals to stay curious and interested in order to be productive and successful. ----- Links: *Arnon LinkedIn *Cleveland Diagnostics *Harsh Thakkar LinkedIn *Would you rather watch on YouTube, Click HERE 👍 Like this video if you enjoy deep dives into healthcare innovations. 🔔 Subscribe to our channel Life Sciences 360 for more expert insights into the rapidly evolving world of life sciences. 📲 Follow us on social media to keep up with the latest news and discussions in the biotech and pharmaceutical sectors and Leave us a Review. -----  Show Notes: (00:00) Introduction and Background (06:26) Choosing Cleveland as a Startup Location (13:13) Balancing Over-Screening and Under-Treating in Cancer Diagnostics (18:57) Proteins Involved in the Disease Process (26:41) The Importance of a Solution that Fits the Final Application (29:05) The Power of Curiosity and Interest in a Career (31:18) Final Thoughts and Advice For transcripts, check out the podcast website - www.lifesciencespod.com

How On-Demand Cleanrooms Can Speed Up Drug Development

28 min

With the market estimated to reach $11.5 billion by 2028. Clean Rooms on Demand is providing flexible and cost-effective solutions for biotech and pharma companies. The benefits of using clean rooms on demand include avoiding the high capital outlay and ongoing operational expenses of building and maintaining their own facilities, as well as the flexibility to scale up or down as needed. Join me in Episode 43 of Life Sciences 360, with Sarah Stevens, the President of Azzur Labs and Azzur Cleanrooms on Demand, part of Azzur Group ----- Links: *Sarah Stevens LinkedIn *Azzur Group *Harsh Thakkar LinkedIn *Would you rather watch? Click here.  -----  Show Notes: (0:00) The Growing Cleanroom Technology Market (3:29) Benefits of Cleanrooms on Demand (6:41) A broader view of biotech lab solutions (9:02) Customer Case Studies and Segments (12:22) Expansion and Future Plans of Azzur Labs (14:29) Global Expansion and Strategic Vision (16:47) Sarah Stevens' Personal Career Journey  (21:26) The Azzur Culture and Team Dynamics For transcripts, check out the podcast website - www.lifesciencespod.com

Beyond the Pill: When Medicine Meets Mindset with CEO, Will Hind

30 min

How can behavioral science optimize pharmaceutical practices? Episode 042: Will Hind, CEO of Alpharmaxim Healthcare Communications, discusses the challenges and opportunities in integrating behavioral science with pharma strategies. Find out how this can lead to better patient outcomes and more tailored healthcare solutions. ----- Links: *Will Hind LinkedIn *Will Hind X *Alpharmaxim *Harsh Thakkar LinkedIn *Would you rather watch the episode? Click here! 📝 Leave us a review! 🔔 Subscribe to our channel, Life Sciences 360, for more expert insights into the rapidly evolving world of life sciences. 📲 Follow us on social media to keep up with the latest news and discussions in the biotech and pharmaceutical sectors. ----- Show Notes: (0:00) Introduction to Behavioral Science in Pharma (1:33) Why is behavior important in pharma? (3:09) Data Analysis and Behavioral Science (6:50) Breaking Down Barriers with Behavioral Science (9:44) The Biggest Misconception of Behavioral Sciences (10:52) Research & Clinical Trials (14:49) The COM-B Model and Pharma Communication (17:52) Multi-stakeholder Influence on Drug Adoption (22:33) Role of Behavioral Science in Omni-channel Marketing (26:21) Future of Behavioral Science in Pharma For transcripts, check out the podcast website - www.lifesciencespod.com

The 3 Most Important Pillars of a Next-Generation CDMO, Explained!

34 min

Episode 041: J.D. Mowery, President and CEO of KBI Biopharma, discusses his career journey and the role of CDMOs in the biotech and pharma industry. He emphasizes the importance of relationships, risk-taking, and continuous learning in his career success. J.D. highlights the unique combination of expertise required to work in both biotech and CDMO companies. He explains the challenges faced by biotech and pharma companies that have led to the rise of CDMOs. Harsh asks J.D. to share the key factors to consider when selecting a CDMO. They introduce the concept of a next-generation CDMO, focusing on regulatory leadership, R&D and innovation, and risk sharing. ----- Links: *J.D. Mowery LinkedIn *KBI Biopharma *Harsh Thakkar LinkedIn *Would you rather watch the episode? Click here!  📝 Leave us a review! 🔔 Subscribe to our channel, Life Sciences 360, for more expert insights into the rapidly evolving world of life sciences. 📲 Follow us on social media to keep up with the latest news and discussions in the biotech and pharmaceutical sectors. ----- Show Notes: (0:00) Intro to J.D. Mowery &KBI Biopharma (3:49) J.D.'s Journey from Biotech to CDMO (7:17) Biopharma Challenges driving the CDMO trend (11:47) What to Look for in a CDMO (14:18) The 3 MOST important pillars of next-gen CDMO (22:05) Team Leadership & Culture at KBI (25:28) What J.D. looks for in a New Team Member (30:32) Most Rewarding Aspect of Working in Life Sciences (32:21) Stay in Touch with J.D. For transcripts, check out the podcast website - www.lifesciencespod.com

Use This Tech, Transform Science: Flow Meters w/ Bethany Silva

20 min

Are you interested in how the latest flow technology is transforming biopharmaceutical manufacturing? Join us for Episode 40 of the Life Sciences 360 podcast, where Harsh Thakkar (@harshvthakkar), CEO of Qualtivate sits down with Bethany Silva (@bethany-silva), Life Sciences Industry Manager at Endress+Hauser. They delve deep into the world of flow measurement, focusing on the cutting-edge single-use flow meters based on the Coriolis principle and how this technology is crucial for the development and production of biologics. 👍 Like this video if you find the advancements in biopharmaceutical manufacturing exciting. 💬 Comment below with your thoughts on how technology is shaping the future of medicine production. 🔔 Subscribe to our channel for more insights from industry leaders and experts in life sciences. 📲 Follow us on social media to stay updated with the latest trends and discussions in the biotech and pharmaceutical industry. ----- Links: *Endress + Hauser *Would you rather watch the episode? Click here. *Like & Subscribe to Life Sciences 360 YouTube Channel! ----- Show Notes: (0:00)  Introduction to Flow Technology in Biopharmaceuticals (1:17)  Understanding Single-Use Flow Meters (4:14) The Cost, Maintenance, and Calibration of Flow Meters (10:10) Application Across Various Industries (13:32) Future Trends in Flow Measurement Technology (16:21) Advice for Aspiring Professionals in the STEM Field (19:10) How to Approach Leadership  For transcripts, check out the podcast website - www.lifesciencespod.com

Democratizing Cell Therapy: A PhD's Quest to Change Medicine Forever

32 min

Toon Lambrechts, co-founder of MyCellHub, shares his journey in democratizing access to cell and gene therapy. He discusses the challenges in cell therapy manufacturing, including the high costs and complex logistics. MyCellHub aims to reduce manufacturing costs and automate processes to make cell therapies more affordable and accessible. Toon emphasizes the importance of networking and collaboration in building a successful team. He also discusses the future of the industry, including the use of natural language processing and automation. MyCellHub's ultimate goal is to scale up cell therapies and make them accessible to everyone. Episode 39: Harsh Thakkar (@harshvthakkar) interviews Toon Lambrechts (@toon-lambrechts). ----- Links: *MyCellHub *Would you rather watch on YouTube? ----- Show Notes: (0:00) Challenges in Cell Therapy (6:12) Cell Therapy Manufacturing Costs & Automation (12:48) Building a Data Management Platform (18:47) Entrepreneurship, Innovation, & Technology (24:35) Using AI in Cell & Gene Therapy For transcripts, check out the podcast website - www.lifesciencespod.com

No Vision, No Problem: How Aaron Golub Redefined Possible

19 min

Aaron Golub, a consultant and speaker, shares his story of overcoming adversity as a legally blind athlete and ex-NFL free agent. He discusses his journey from being a third-string high school athlete to becoming the first legally blind Division I athlete. Aaron also talks about his transition from sports to a career in finance and eventually to consulting with companies. He emphasizes the importance of qualities such as resilience, empathy, and effective communication in leadership. Aaron shares his perspective on coping with personal adversity and tailoring his advice for different audiences. He aims to be remembered as someone who gave his all to help others succeed. Episode 038: Harsh Thakkar (@harshvthakkar) interviews Aaron Golub (@aarongolub), Consultant Speaker, helping organizations implement leadership strategies and overcome adversity. ----- Links: *Aaron's website  *Aaron's email (aaron@aarongolub.com) ----- Show Notes: (0:00) Overcoming adversity in sports and life. (4:06) Defeating the odds and inspiring others. (9:01) Leadership development and personal resilience. (14:44) Finding gratitude and success despite hardship. For transcripts, check out the podcast website - www.lifesciencespod.com

His Strategy and Success Story with the MedTech Startup: FastWave

26 min

He scaled his business from 0 to 20 million in under 3 years. Get inspired by the story of Scott Nelson's strategic brilliance and entrepreneurial triumph with Joovv and FastWave Medical, a groundbreaking MedTech startup reshaping the industry landscape. Learn about the strategic decisions, challenges overcome, and pivotal moments that defined Scott's path to success. Harsh and Scott also discuss the challenges and rewards of transitioning from working with large strategic companies to early-stage startups. They emphasize the importance of taking risks, learning from experiences, and being prepared for the ups and downs of entrepreneurship. You're watching Episode 037: Harsh Thakkar (@harshvthakkar) interviews Scott Nelson (@scottnelsonlive), Co-Founder, President, & CEO of FastWave Medical. ----- Links: *Fast wave medical *Joovv *If you enjoy this type of content, or would like to watch this episode, subscribe and give us a like on YouTube ! ----- Show Notes: (0:00) Entrepreneurship, Med-Tech, and startup journey. (2:40) A new medical device for treating complex artery disease. (6:04) Transitioning from corporate to startup life.  (9:38) Career advice and growth strategies for startups & entrepreneurs. (13:52) Learning from experience. (18:48) Decision-making, and consumer health trends. (21:10) Perfect is the enemy of good. For transcripts, check out the podcast website - www.lifesciencespod.com

See all 86 episodes

–

0 ratings from members

5
4
3
2
1

Rate this podcast

Log in to rate and review the shows you listen to.

No reviews yet — be the first member to rate "Life Sciences 360".

This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.

Keep listening

Discover more podcasts like this.

Browse podcasts See the charts

Up next

  1. Nothing queued. Use + Queue on any episode to line it up.

0:00 0:00

Cookies

We set only what the site needs to sign you in and remember your theme. No advertising, no analytics. Read more.